Notable
ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
Primary completion pushed from Dec 1, 2026 to Jun 1, 2028
Also in this update: Study completion pushed from May 1, 2027 to Nov 1, 2028
SciTech Development, Inc.Phase 1 NCT04234048 Registry history of NCT04234048 on ClinicalTrials.gov (opens the registry)